LOTTE BIOLOGICS has been honored at the 2024 KSBB Spring Meeting and International Symposium held at the Changwon Exhibition & Convention Center (CECO) on Thursday, April 18th.

The Korean Society of Biotechnology and Bioengineering(KSBB), the country's leading biotechnology association with more than 10,000 members, annually recognizes companies that have made significant contributions to the development of the biotech industry in Korea.

LOTTE BIOLOGICS was recognized for not only entering the CDMO market with the successful acquisition of Bristol-Myers Squibb (BMS)'s Syracuse site in New York, USA, but also for its large-scale investment in the Songdo Bio Plant which began construction in March 2024, recruiting a significant pool of new talent in the bio industry and contributing to high-quality job creation.